Key Takeaways
- Anterra Capital has reached a $100 million first close on its Fund III, against a target of $200 million, with a focus on technology companies transforming food and agriculture from within existing industry infrastructure.
- The fund has already made two investments: Anchr, an AI-native platform modernising food distribution back-office operations, and Animerra, a veterinary biologics company founded and built by Anterra itself.
- Anterra's investor base includes the world's largest food and agriculture bank, a leading Asian sovereign wealth fund, the world's largest animal health company, and operators farming more than 13 million acres combined.
- The firm's prior portfolio includes Invetx, acquired by Dechra Pharmaceuticals for over $500 million within six years of being founded by Anterra, and Enko Chem, a next-generation crop protection company partnered with Syngenta and Bayer Crop Science.
- Global agrifood tech investment fell from a peak of nearly $52 billion in 2021 to roughly $16 billion — returning to 2016 levels — a reset Anterra views as opening the field for disciplined, specialist investors.
Anterra Capital Hits $100M First Close on Fund III
Anterra Capital has announced a $100 million first close on its third fund, with a fundraising target of $200 million. The firm, which describes its approach as backing companies that transform food and agriculture through existing industry channels rather than rebuilding the system from scratch, positions Fund III as the product of twelve years of sector-specific investing across two prior capital cycles.
The close comes as broader agrifood tech investment has pulled back sharply from its 2021 peak, with global capital flows dropping from nearly $52 billion to around $16 billion — levels last seen in 2016. Anterra views that contraction as clearing the market of generalist capital and creating conditions that favour specialist investors with deep sector knowledge.
“The firm has now successfully navigated two capital cycles in food and agriculture. Each one rewarded the same discipline: backing companies that deliver real returns for their customers and to their investors. What's different this time is that the real-world industries we operate in — large, complex and historically resistant to change — are now ready to be rewired, and the tools to do it have arrived,” said Maarten Goossens, Partner at Anterra Capital.
Why Now: AI, Biology, and a Reset Capital Cycle
Anterra's case for Fund III centres on two converging forces. The first is vertical AI, which the firm describes as the fastest-growing category in enterprise technology, with investment tripling in a single year. Applied to food and agriculture — industries that still run largely on manual workflows, fragmented data, and analogue infrastructure — it is enabling a wave of digitisation that earlier software never reached.
The second is AI's effect on biology. The firm argues that AI is compressing R&D timelines, reducing team sizes, and cutting the capital required to reach a first commercial milestone in life sciences — opening up a generation of opportunities in crop protection, animal health, and agricultural biology that were previously too expensive for venture capital to pursue.
Food and agriculture remains the largest industry on the planet at roughly $10 trillion in size, employing approximately 1.3 billion people. Anterra points to converging pressures — margin volatility, food security concerns, climate and water constraints, tightening regulation, and shifting health outcomes — as forces making the status quo increasingly difficult to sustain across the value chain.
Anterra Capital's Track Record and Portfolio Companies
Anterra's first two funds produced what the firm describes as top-tier returns, including a Nasdaq IPO and several acquisitions by major industry players. Its most prominent exit to date is Invetx, a veterinary medicine company the firm founded in 2018 and built from inception. Invetx applied biological approaches from human medicine to animal health and was acquired by Dechra Pharmaceuticals for over $500 million within six years of being established — one of the largest early-stage exits in veterinary medicine.
A second company creation, Enko Chem, is developing next-generation crop protection chemistry through rational design, targeting replacements for older chemistries, and has secured partnerships with Syngenta and Bayer Crop Science.
Fund III's first two investments continue the company-building model. Anchr is an AI-native platform aimed at modernising the back office of food distribution, a sector the firm estimates at roughly $1 trillion and still largely paper-based — backed alongside a16z Speedrun. Animerra is a veterinary biologics company founded and built by Anterra, advancing its science with a lean team at a pace the firm says would not have been possible five years ago.
Who Is Backing Fund III
Anterra Capital's investor base for Fund III spans institutional investors, food system operators, and industry innovators across North America, Europe, and Asia-Pacific. Named categories of backers include the world's largest food and agriculture bank, one of the largest life sciences investors globally, a leading Asian sovereign wealth fund, and the world's largest animal health company. The operator cohort collectively farms more than 13 million acres and includes leaders from large CPG, bakery, produce logistics, and food retail businesses.
“The vote of confidence from our investor base is what gives this close its weight. The combination of leading global asset managers, the institutions that know our sector backwards and the operators who farm millions of acres all backing the same thesis is an unrivalled force supporting the Anterra portfolio,” said Adam Anders, Partner at Anterra Capital.
“We've spent twelve years and two funds proving you can build category-defining companies in food and agriculture — and generate real returns doing it. What's changed is that the world has finally caught up to that thesis. The technology is here, the valuations make sense, and the founders building in this sector are the best we've ever seen. This is the most exciting moment in our firm's history, and Fund III is how we intend to make the most of it,” said Brett Wong, Partner at Anterra Capital.
